Search Results
Sep 25, 2025, 10:30 ET Mint Pharmaceuticals Announces Partnership with Bayer Canada to Distribute ADALAT® XL® (nifedipine extended-release tablets) 30 mg Tablets in Canada
/PRNewswire/ - Mint Pharmaceuticals Inc. is pleased to announce a new partnership with Bayer Canada for the distribution of ADALAT® XL® 30 mg tablets
More news about: Mint Pharmaceuticals
Sep 25, 2025, 10:00 ET Tia Health and Molecular Testing Labs Partner to Launch the First-Ever FDA-Cleared Home-Collected 4-Plex STI Test
common STIs — Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) — in a single collection, making it efficient, cost-effective, and comprehensive. Patients can access the test kit through an order from one of Tia's
More news about: Molecular Testing Labs
Sep 25, 2025, 08:43 ET Death Wish Coffee Co. Delivers Bold, Bottled Format with New Multi-Serve Cold Brew
bold, unsweetened Dark Roast is brewed for 18 hours to deliver rich flavor and sustainable strength. With only 10 calories and approximately 265mg of natural caffeine per serving, Death Wish Coffee Co.'s Organic Cold Brew is made with just one ingredient – coffee. Containing zero sugar, artificial
More news about: Death Wish Coffee Co.
Sep 25, 2025, 08:00 ET Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"
demonstrating a mean improvement in latency to persistent sleep (LPS) from baseline to the average of Nights 1 and 8 of 44.9 minutes (20 mg) and 46.3 minutes (50 mg) versus 28.2 minutes (placebo) (p < 0.001). Improvements in LPS persisted through the follow-up time points (Nights 22 and 29, p < 0.01).
More news about: Vanda Pharmaceuticals Inc.
Sep 25, 2025, 08:00 ET Introducing SwimClub™: The First Clinically-Formulated Male Fertility Supplement
Statistics Reports. 2019.Safarinejad MR. Biol Trace Elem Res. 2011.Aksoy Y, et al. Andrologia. 2018.Showell MG, et al. Cochrane Database Syst Rev. 2019.Safarinejad MR. J Urol. 2009.Balercia G, et al. Fertil Steril. 2005.Boxmeer
More news about: Squared Circles
Sep 25, 2025, 07:00 ET Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress
and multiple ascending dose (Part B) cohorts. Results from Part A will be presented. GB-0895 was well tolerated across a wide dose range of 10 mg to 1200 mg and demonstrated dose-proportional pharmacokinetics with a prolonged half-life of ~89 days. Sustained reductions in eosinophils, FeNO, IL-5, and
More news about: Generate:Biomedicines
Sep 25, 2025, 06:30 ET Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
demonstrated a favorable safety and tolerability profile, with similar rates of adverse event rates compared to placebo and no new safety signals at the 45 mg once-daily dose. Overall, the CALLIPER trial data support advancing vidofludimus calcium into phase 3 studies for PMS." Late Breaking Poster
More news about: Immunic, Inc.
Sep 24, 2025, 13:18 ET Fusion CBD Products' Sleep and Recovery Softgels Could Help You Conquer Insomnia
and Recovery Softgels can help. Made from premium hemp grown in the USA, they contain 25 mg of broad spectrum hemp extract as well as 3 mg each of cannabinol and melatonin. One capsule taken 30 minutes before you hope to fall asleep may improve your sleep quality and
More news about: Fusion CBD Products
Sep 24, 2025, 10:40 ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed
More news about: Faruqi & Faruqi, LLP
Sep 24, 2025, 09:48 ET UK Company Solves Prebiotic Problem with Low-Dose Seaweed Extract Proven to Work Without the Bloat
effects. Their new seaweed-derived ingredient, OCEAN ACTIVES® H+, delivers the same microbiome benefits as traditional bulky prebiotics with only 250 mg per day – about the size of a vitamin C tablet. The breakthrough addresses a major consumer pain point: conventional prebiotics like inulin,
More news about: OCEANIUM LTD
Sep 23, 2025, 16:15 ET Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line with Three New Concentrations
include premixed IV bags in five concentrations: 2 mg, 4 mg, 5 mg, 8 mg, and 10 mg per 250 mL. The portfolio also includes ADRENALIN® (epinephrine injection, USP) in 1 mL single-dose and 30 mL multi-dose vials. The 5 mg/250 mL and 10 mg/250 mL concentrations align with the American Society
More news about: Endo USA, Inc.
Sep 23, 2025, 10:01 ET With 5% CAGR Paracetamol Market is expected to grow US$15.03 billion by 2031, surging amid the Growing Pharmaceutical Industry | The Insight Partners
on Paracetamoli) Marksans Pharma announced that its subsidiary, Relonchem, received marketing authorization for Ibuprofen and Paracetamol 200 mg/500 mg film-coated tablets.ii) The Council of Scientific and Industrial Research (CSIR) has launched its domestically produced paracetamol in
More news about: The Insight Partners
Sep 23, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed
More news about: Pomerantz LLP
Sep 23, 2025, 08:30 ET Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden
initial dose of 40 mg for four weeks, with the option to adjust the dose to 60 mg or 80 mg through Week 16, followed by a stable dose through Week 24. At Week 24, 26 of 45 patients (57.8%) achieved the remission threshold, including 58.3% at 40 mg, 44.4% at 60 mg and 62.5% at 80 mg. The threshold for
More news about: Neurocrine Biosciences, Inc.
Sep 22, 2025, 22:16 ET Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
Cohort 1 and 2, the Phase 2 stage of the KL400-I/II-01 study, evaluate the efficacy and safety of A400/EP0031 90mg orally once daily (QD) for the treatment of patients with pre-treated and treatment-naïve RET-fusion positive locally advanced, or metastatic NSCLC,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sep 22, 2025, 16:53 ET GORGIE Partners with Gopuff to Launch Limited-Edition Cosmic Berry Energy Seltzer
Made with 150mg green tea caffeine, L-theanine, biotin, and B vitamins, Cosmic Berry delivers GORGIE's signature better-for-you buzz with only 5 calories and 0g sugar.
More news about: GORGIE
Sep 22, 2025, 13:14 ET Support Immune Health with 4 Everyday Habits
serving: 250 calories; 5 g protein; 25 g carbohydrates; 16 g fat (58% calories from fat); 2.5 g saturated fat (9% calories from saturated fat); 0 mg cholesterol; 320 mg sodium; 3 g fiber. Michael French
More news about: Family Features Editorial Syndicate
Sep 22, 2025, 11:28 ET Due Diligence Concluded / Commencement of Definitive Agreement
Equivalent ("LCE") Resource at an average grade of 736 milligrams per liter lithium (mg/L Li ) , with 1,463,000 tonnes in the measured category and 120,000 tonnes in the indicated category, at a cutoff grade of 500 mg/l Li (Note 1 below) on the Alba Sabrina, Natalia Maria,
More news about: Lithium South Development Corporation
Sep 22, 2025, 08:30 ET Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
Day 56: osavampator 1 mg maintained statistical significance; 3 mg showed favorable but nominal differenceRemission (MADRS score ≤10): Day 56: osavampator 1 mg achieved statistically significant improvement versus placebo; 3 mg showed numerical improvement
More news about: Neurocrine Biosciences, Inc.
Sep 22, 2025, 08:05 ET European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU
(CNS WHO grade 4) VORANIGO IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS What is VORANIGO? VORANIGO (40 mg tablets) is a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called astrocytoma
More news about: Servier Pharmaceuticals
Sep 22, 2025, 07:45 ET Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
to Xyrem. Xywav has 131 mg of sodium at the maximum recommended nightly dose whereas other high sodium oxybates have 1640 mg at the equivalent dose. Xywav is comprised of a unique composition of cations resulting in 92% less sodium, or a reduction of approximately 1,000 to 1,500 mg/night at the recommended
More news about: Jazz Pharmaceuticals plc
Sep 22, 2025, 07:00 ET Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively. Skin CancersIn ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated
More news about: Insmed Incorporated
Sep 21, 2025, 20:10 ET Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy
different single doses (10 mg, 30 mg and 60 mg) of ASC47 in combination with four weekly doses of 0.5 mg semaglutide. The effect on fat and lean mass was not an objective of this study given the short treatment duration (28 days). On day 29, a single SQ dose of 30 mg ASC47 in combination with
More news about: Ascletis Pharma Inc.